X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Apollo Hospitals: Numbers disappoint - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Nov 29, 2002

    Apollo Hospitals: Numbers disappoint

    Apollo Hospitals Enterprises Limited, the healthcare major, has announced poor September quarter results. At first glance a topline growth of 16% and a bottomline growth of 33% on a YoY basis look attractive. A closer look reveals that due to the more than proportionate rise in expenditure, operating profits have actually fallen. Bottomilne growth has been aided by considerable rise in other income and fall in taxes. Net profits have actually fallen if the effect of other income were to be removed.

    (Rs m) 2QFY02 2QFY03 Change 1HFY02 1HFY03 Change
    Net Sales 943 1,096 16.2% 1,768 2,147 21.4%
    Other Income 12 39 225.0% 46 53 15.2%
    Expenditure 730 902 23.6% 1,393 1,739 24.8%
    Operating Profit (EBDIT) 213 194 -8.9% 375 408 8.8%
    Operating Profit Margin (%) 22.6% 17.7%   21.2% 19.0%  
    Interest 65 65 0.0% 112 125 11.6%
    Depreciation 45 57 26.7% 85 115 35.3%
    Profit before Tax 115 111 -3.5% 224 221 -1.3%
    Extraordinary items - -   - -  
    Tax (58) (35) -39.7% (88) (76) -13.6%
    Profit after Tax/(Loss) 57 76 33.3% 136 145 6.6%
    Net profit margin (%) 6.0% 6.9%   7.7% 6.8%  
    No. of Shares 39.5 39.5   39.5 39.5  
    Diluted Earnings per share* 5.8 7.7   6.9 7.3  
    P/E Ratio   13.8     14.4  
    (* annualised)            

    On half yearly basis, the story is not too different. While topline has shown impressive growth, higher expenditure has eaten in to operating profits. Bottomilne growth is just marginal if it were not for rise in other income. Topine growth has been mainly due to addition of new beds in the last one year. In the past year the company has added a total of 450 beds to owned beds capacity. Topline growth has come at a price, the estimated 20% rise in bed capacity have added to the costs, which are likely to yet achieve operational break-even. A rise in sale of low margin pharma business may also have been a cause of margins declining in the given period.

    In both periods depreciation costs have increased considerably. Addition of new beds is the likely reason for the same. During FY02, AHEL commissioned a new speciality hospital in Colombo, Sri Lanka. The hospital has a capacity of nearly 500 beds and the company holds a 31% equity in the venture. AHEL is agressively trying to tap new markets mainly in west Asia. The company plans to set up another speciality hospital in Sri Lanka encouraged by incentives given by the local government. Apollo Hospitals has been borrowing for starting up these ventures in India and abroad this has led to an increase in the debt levels and a consequent rise in the company's interest outgo.

    The company has however stated that it does not plan any capital expenditure on new hospitals and plans to concentrate on increasing the hospitals under management. AHEL plans to increase the ratio between managed beds and owned beds to 1.5:1 from the current ratio of 1:1. At present nearly 79% of the total capital employed is towards the hospital division, which includes the pharmancy division.

    At Rs 105 the stock is trading at a P/E of 14 its annualised 1HFY03 earnings. The company has been exhibiting a volatile trend as far as financial performance is concerned. The company's performance in 1QFY03 was encouraging but its performance in 2QYF03 has been disappointing. There has been a consistent drop in the company's operating margins due to higher contribution to revenues from the low marging pharmaceutical business.

    The company's focus on managed beds is a step in the right direction but it will be a while before revenues from this stream actually contribute significantly to the bottomline. Interest and depreciation costs may come down going forward due to no planned capacity additions. Operating margins, on the other hand, may face correction as managed bed revenues increase. The stock seems to be fairly valued.

     

     

    Equitymaster requests your view! Post a comment on "Apollo Hospitals: Numbers disappoint". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    APOLLO HOSPITALS SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK APOLLO HOSPITALS

    • Track your investment in APOLLO HOSPITALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON APOLLO HOSPITALS

    APOLLO HOSPITALS - FORTIS HEALTHCARE COMPARISON

    Compare Company With Charts

    COMPARE APOLLO HOSPITALS WITH

    MARKET STATS